Spironolactone AmiLoride Thiazide study of aldosterone sensitive hypertension

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN85520592

Enrollment

Registered

2002-03-28

Start date

2003-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low-renin hypertension Circulatory System Hypertension

Interventions

Spironolactone (50 & 100 mg), amiloride (20 & 40 mg), bendrofluazide (2.5 & 5 mg), irbesartan (150 mg), placebo. The lower dose of each will be re-encapsulated in identical capsules. Patients will ta

Eligibility

Inclusion criteria

Inclusion criteria: 1. Hypertension (requiring treatment according to British Hypertension Society [BHS] criteria) 2. Aldosterone/renin ratio >400 3. Either Systolic Blood Pressure (SBP) on spironolactone more than or equal to 20 mmHg, during previous open-label treatment or Plasma renin activity less than 0.2 pmol/ml/h and response to spironolactone not previously tested

Exclusion criteria

Exclusion criteria: Contraindications to study drugs

Design outcomes

Primary

Measure	Time frame
sBP and plasma renin on spironolactone versus bendroflumethiazide.	—

Secondary

Measure	Time frame
1. sBP on amiloride versus other diuretics. 2. Further measures of natriuresis.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026